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We read with interest the editorial by Orvieto and Seifer
[1] on the EU approved r-hFSH biosimilar products Ova-
leap® [2] and Bemfola® [3] and the reference Gonal-f®. We
were surprised by the negative tone and seeming dismissal
of EMA guidelines [4] for the development and marketing
authorization of r-hFSH biosimiliars. The editorial ques-
tions the legal basis for r-hFSH biosimilar registration and
use in clinical practice. We comment on the development
and role of r-hFSH biosimilars and correct errors and
omissions in the editorial.
The phase 3 Bemfola® and Ovaleap® populations are re-
ferred to as “ideal” patients in the editorial. Not recog-
nized is that the phase 3 studies that supported Gonal-f®
and Puregon® used similar patient populations and add-
itional data were generated after the products became
available for clinical use.
After acknowledging that the mean number of oocytes
retrieved (EMA recommended primary efficacy outcome)
was equivalent with the reference Gonal-f® and safety was
comparable, the editorial re-interprets the non-significant
differences between groups in pregnancy and OHSS
(secondary endpoints) and suggests the biosimilars and
reference r-hFSH products are not comparable. The edi-
torial pooled Bemfola® and Ovaleap® data but did not in-
clude the caveat that different study protocols were used
(e.g., randomization schemes, different GnRH agonists,
dose adaptations). These differences likely place limita-
tions on pooled comparisons. Importantly, number of oo-
cytes retrieved is a clinically meaningful surrogate for
successful live birth [5], the primary aim of IVF treatment.
Pregnancy and live birth rates are problematic as they
may be influenced by factors beyond r-hFSH treatment –
date of embryo transfer, embryo transfer regional policies,
luteal phase support, etc…
Clinically meaningful errors or omissions were made
that favored the superiority of Gonal-f® over the biosimi-
lar product:
 “Gonal-f® group achieved non-significantly more oo-
cytes” than the Bemfola® group. However, this refers
to FSH treatment duration and not to the number
of oocytes retrieved. Interestingly, it was the Bem-
fola® group that achieved non-significantly more
oocytes.
 “the Gonal-f® group achieved non-significantly lower
peak E2 levels and lower cancellation rate with the
consequent decreased incidence of OHSS.” However,
study data [2] showed that cancellation rate was actu-
ally lower in the Ovaleap® group. And, this statement
suggests a link between “non-significantly lower” E2
peak level and “decreased incidence” of OHSS, even
though OHSS rates were not significantly different
between groups (P = 0.542) [2]. Although OHSS inci-
dence was low in both groups, it led to more treat-
ment discontinuation with Gonal-f® (2) than with
Ovaleap® (1).
Conclusion
The editorial appears to argue that biosimilar products
should not be considered in clinical practice, constrain-
ing the role of r-hFSH biosimilars as simply “a regulatory
synonym," thereby promoting the reference product as
the sole treatment option. We maintain women should
have access to approved alternative treatment options
with demonstrated comparable efficacy and safety, as oc-
curs in the development of r-hFSH biosimilar products
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in response to EMA guidelines. Such options may im-
prove health care and lower financial burden. Clinicians
should be able to select an approved r-hFSH product at
their discretion based on individual patient characteris-
tics and clinical needs.
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We thank Strowitzki et al. for their letter. The editorial
was not meant to be negative to any product (biosimilar or
the reference products), or to recommend against the use
of biosimilar products in clinical practice, but to describe
the biological differences between the products and to pro-
vide a brief overview of the published clinical studies.
Biosimilars are legitimate products, and are a wel-
comed addition to the FSH armamentarium. We have
not “questioned the legal basis” of biosimilar registra-
tion, but rather, have called for caution while imple-
menting a new product to the COH armamentarium. As
we have already stated and clearly described, since biosi-
milars are not identical to the reference products, and
due to the fact that the clinical experience gained with
their use came from RCT’s which included “ideal”, best
prognosis patients, we believe that for patients’ safety,
“further comparative studies are needed in other patient
populations that are encountered during routine daily
clinical practice, e.g., older, poor responders, patients with
repeated IVF failures or high responders, such as those
with polycystic ovary syndrome, before the universal
implementation of biosimilar products to clinical use”.
Moreover, this is also why we recommend “against inter-
changing or substituting innovator and biosimilar agents
in clinical practice, and believe that the decision whether
to use an innovator or a biosimilar product, should be re-
served to the discretion of the treating physician”.
Specific comments:
We do not doubt, neither did we attempt to challenge
the legitimacy of the biosimilar products registration, the
EMA regulations or decisions. As mentioned above, bio-
similars are legitimate products and are a welcomed
addition to the FSH armamentarium.
The fact the RCTs (those supporting the use of Gonal-
f and Puregon) were conducted in “ideal” patients, does
not mean that caution should not be taken while treat-
ing “non-ideal” patients.
The clinical data, as presented in the Editorial, sum-
marized the two RCT’s and did not mean to replace
them. As stated, Table 2 simply gathered the data from
the 2 RCTs and was not meant to conduct a sophisti-
cated statistical analysis. Its intent was to support the no-
tion that biosimilars are not “identical twins”. Moreover,
the cancellation rate was non-significantly lower in the
Gonal-f, as compared to the Bemfola group. No mention
was made in the Editorial regarding cancellation rate in
the Ovaleap Study.
We thank Strowitzki et al. for their correction regarding
the oocyte number (which was stated correctly in the
table, but not in the text). An erratum has been published
accordingly.
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